Clinical Scorecard: Evaluating Adverse Reactions and Perceived Advantages of Pharmacotherapy in Pediatric Patients with Chronic Non-Cancer Pain
At a Glance
Category
Detail
Condition
Chronic non-cancer pain in pediatric patients
Key Mechanisms
Pharmacological interventions including antiepileptics, antidepressants, NSAIDs, Tramadol; assessment of adverse effects and perceived benefits
Target Population
Children and adolescents aged 7–17 years with chronic primary or secondary pain
Care Setting
Tertiary care interdisciplinary pain program
Key Highlights
Adverse effects occurred in 81% of patients within the first four weeks of pharmacologic treatment, with gastrointestinal and attention-related effects most common.
Perceived benefits were reported by 77% of patients, primarily analgesic benefit (64%) and sleep improvement (49%).
Polypharmacy increased the incidence of adverse effects but also the number of benefited domains per patient; however, benefits per prescription decreased with more medications.
Guideline-Based Recommendations
Diagnosis
Identify chronic pain lasting more than 3 months in pediatric patients.
Use interdisciplinary assessment to classify primary or secondary chronic pain.
Management
Employ pharmacological treatments as part of interdisciplinary care, considering antiepileptics, antidepressants, NSAIDs, and Tramadol.
Monitor for adverse effects especially during the first month of treatment.
Engage patients and caregivers in shared decision-making regarding risks and benefits.
Be cautious with polypharmacy due to increased adverse effect risk.
Monitoring & Follow-up
Systematically assess adverse effects within four weeks of initiating new medications.
Evaluate patient-reported benefits in pain, sleep, physical function, and mood as independent domains.
Use quality improvement frameworks such as PDSA cycles for ongoing safety and efficacy monitoring.
Risks
High incidence of adverse effects, particularly gastrointestinal and attention-related symptoms.
Increased adverse effects with multiple concomitant medications.
Potential for nocebo effects influencing adverse event reporting.
Lack of pediatric-specific drug approvals and warnings for increased suicidal ideation risk with gabapentinoids and antidepressants.
Patient & Prescribing Data
142 pediatric patients aged 7–17 years, predominantly female (90%), receiving pharmacologic treatment for chronic pain.
Patients received an average of 2 prescriptions; adverse effects were common and increased with polypharmacy, while perceived benefits were reported in multiple domains but decreased per prescription with more medications.
Clinical Best Practices
Incorporate interdisciplinary approaches combining pharmacological and non-pharmacological therapies.
Closely monitor for adverse effects early in treatment, especially with polypharmacy.
Engage patients and caregivers in discussions about expected benefits and potential risks.
Use real-world quality improvement methods to iteratively assess treatment safety and efficacy.
Recognize limitations of current evidence and the need for pediatric-specific pharmacological research.
